OBJECTIVE: To compare clinical, immunologic and virologic outcomes among stable HIV-positive patients down-referred to a nurse-managed primary healthcare clinic (PHC) for treatment maintenance to those who remained at a doctor-managed treatment-initiation site. DESIGN: We conducted a matched cohort analysis among stable HIV patients at the Themba Lethu Clinic in Johannesburg, South Africa. Eligible patients met the criteria for down-referral [undetectable viral load <10 months, antiretroviral therapy (ART) >11 months, CD4 cell count ≥200 cells/μl, stable weight and no opportunistic infections], regardless of whether they were down-referred to a PHC for treatment maintenance between February 2008 and January 2009. Patients were matched 1 : 3 (down-referred : treatment-initiation) using propensity scores. METHODS: We calculated rates and hazard ratios (HRs) for the effect of down-referral on loss to follow-up (LTFU) and mortality and the relative risk of down-referral on viral rebound by 12 months of follow-up. RESULTS: Six hundred and ninety-three down-referred patients were matched to 2079 treatment-initiation patients. Two (0.3%) down-referred and 32 (1.5%) treatment-initiation patients died, 10 (1.4%) down-referred and 87 (4.2%) treatment-initiation patients were lost, and 22 (3.3%) down-referred and 100 (5.6%) treatment-initiation patients experienced viral rebound by 12 months of follow-up. After adjustment, patients down-referred were less likely to die [hazard ratio (HR) 0.2, 95% confidence interval (CI) 0.04-0.8], become LTFU (HR 0.3, 95% CI 0.2-0.6) or experience viral rebound (relative risk 0.6, 95% CI 0.4-0.9) than treatment-initiation patients during follow-up. CONCLUSION: The utilization of nurse-managed PHCs for treatment maintenance of stable patients could decrease the burden on specialized doctor-managed ART clinics. Patient outcomes for down-referred patients at PHCs appear equal, if not better, than those achieved at ART clinics among stable patients.
OBJECTIVE: To compare clinical, immunologic and virologic outcomes among stable HIV-positive patients down-referred to a nurse-managed primary healthcare clinic (PHC) for treatment maintenance to those who remained at a doctor-managed treatment-initiation site. DESIGN: We conducted a matched cohort analysis among stable HIV patients at the Themba Lethu Clinic in Johannesburg, South Africa. Eligible patients met the criteria for down-referral [undetectable viral load <10 months, antiretroviral therapy (ART) >11 months, CD4 cell count ≥200 cells/μl, stable weight and no opportunistic infections], regardless of whether they were down-referred to a PHC for treatment maintenance between February 2008 and January 2009. Patients were matched 1 : 3 (down-referred : treatment-initiation) using propensity scores. METHODS: We calculated rates and hazard ratios (HRs) for the effect of down-referral on loss to follow-up (LTFU) and mortality and the relative risk of down-referral on viral rebound by 12 months of follow-up. RESULTS: Six hundred and ninety-three down-referred patients were matched to 2079 treatment-initiation patients. Two (0.3%) down-referred and 32 (1.5%) treatment-initiation patients died, 10 (1.4%) down-referred and 87 (4.2%) treatment-initiation patients were lost, and 22 (3.3%) down-referred and 100 (5.6%) treatment-initiation patients experienced viral rebound by 12 months of follow-up. After adjustment, patients down-referred were less likely to die [hazard ratio (HR) 0.2, 95% confidence interval (CI) 0.04-0.8], become LTFU (HR 0.3, 95% CI 0.2-0.6) or experience viral rebound (relative risk 0.6, 95% CI 0.4-0.9) than treatment-initiation patients during follow-up. CONCLUSION: The utilization of nurse-managed PHCs for treatment maintenance of stable patients could decrease the burden on specialized doctor-managed ART clinics. Patient outcomes for down-referred patients at PHCs appear equal, if not better, than those achieved at ART clinics among stable patients.
Authors: Badara Samb; Francesca Celletti; Joan Holloway; Wim Van Damme; Kevin M De Cock; Mark Dybul Journal: N Engl J Med Date: 2007-12-13 Impact factor: 91.245
Authors: Charles F Gilks; Siobhan Crowley; René Ekpini; Sandy Gove; Jos Perriens; Yves Souteyrand; Don Sutherland; Marco Vitoria; Teguest Guerma; Kevin De Cock Journal: Lancet Date: 2006-08-05 Impact factor: 79.321
Authors: Ira B Wilson; Bruce E Landon; Lisa R Hirschhorn; Keith McInnes; Lin Ding; Peter V Marsden; Paul D Cleary Journal: Ann Intern Med Date: 2005-11-15 Impact factor: 25.391
Authors: Elvin H Geng; Denis Nash; Andrew Kambugu; Yao Zhang; Paula Braitstein; Katerina A Christopoulos; Winnie Muyindike; Mwebesa Bosco Bwana; Constantin T Yiannoutsos; Maya L Petersen; Jeffrey N Martin Journal: Curr HIV/AIDS Rep Date: 2010-11 Impact factor: 5.071
Authors: Andrew Boulle; Gilles Van Cutsem; Katherine Hilderbrand; Carol Cragg; Musaed Abrahams; Shaheed Mathee; Nathan Ford; Louise Knight; Meg Osler; Jonny Myers; Eric Goemaere; David Coetzee; Gary Maartens Journal: AIDS Date: 2010-02-20 Impact factor: 4.177
Authors: Tom Decroo; Isabella Panunzi; Carla das Dores; Fernando Maldonado; Marc Biot; Nathan Ford; Kathryn Chu Journal: J Int AIDS Soc Date: 2009-05-06 Impact factor: 5.396
Authors: Shabbar Jaffar; Barbara Amuron; Susan Foster; Josephine Birungi; Jonathan Levin; Geoffrey Namara; Christine Nabiryo; Nicaise Ndembi; Rosette Kyomuhangi; Alex Opio; Rebecca Bunnell; Jordan W Tappero; Jonathan Mermin; Alex Coutinho; Heiner Grosskurth Journal: Lancet Date: 2009-11-24 Impact factor: 79.321
Authors: Ashwin Vasan; Nathan Kenya-Mugisha; Kwonjune J Seung; Marion Achieng; Patrick Banura; Frank Lule; Megan Beems; Jim Todd; Elizabeth Madraa Journal: Hum Resour Health Date: 2009-08-20
Authors: Matthew P Fox; Kate Shearer; Mhairi Maskew; William Macleod; Pappie Majuba; Patrick Macphail; Ian Sanne Journal: AIDS Date: 2012-09-10 Impact factor: 4.177
Authors: Matthew P Fox; Mhairi Maskew; A Patrick MacPhail; Lawrence Long; Alana T Brennan; Daniel Westreich; William B MacLeod; Pappie Majuba; Ian M Sanne Journal: Int J Epidemiol Date: 2012-03-20 Impact factor: 7.196
Authors: Maureen A Kelley; Sydney A Spangler; Laura I Tison; Carla M Johnson; Tegan L Callahan; Jill Iliffe; Kenneth W Hepburn; Jessica M Gross Journal: J Nurs Regul Date: 2017-10
Authors: Larry W Chang; David Serwadda; Thomas C Quinn; Maria J Wawer; Ronald H Gray; Steven J Reynolds Journal: Lancet Infect Dis Date: 2013-01 Impact factor: 25.071
Authors: Colette Guiteau Moise; Vanessa R Rivera; Kelly A Hennessey; Clovy Bellot; Chris Nicholas; Anna P Fang; Rose Irène Verdier; Patrice Severe; Alix Sainvil; Benedict Charles; Derothy Dorval; Juseline St Amour; Jean W Pape; Serena P Koenig Journal: J Acquir Immune Defic Syndr Date: 2018-09-01 Impact factor: 3.731
Authors: Wafaa M El-Sadr; Charles B Holmes; Peter Mugyenyi; Harsha Thirumurthy; Tedd Ellerbrock; Robert Ferris; Ian Sanne; Anita Asiimwe; Gottfried Hirnschall; Rejoice N Nkambule; Lara Stabinski; Megan Affrunti; Chloe Teasdale; Isaac Zulu; Alan Whiteside Journal: J Acquir Immune Defic Syndr Date: 2012-08-15 Impact factor: 3.731